Ono Pharmaceutical Co., Ltd. (FRA:ON4)

Market Cap	5.90B +23.3%
Revenue (ttm)	2.90B +4.0%
Net Income	279.29M -49.0%
EPS	0.59 -48.8%
Shares Out	n/a
PE Ratio	21.13
Forward PE	n/a
Dividend	0.47 (3.86%)
Ex-Dividend Date	Sep 29, 2025

Volume	300
Average Volume	15
Open	12.30
Previous Close	12.40
Day's Range	12.30 - 12.30
52-Week Range	8.95 - 12.50
Beta	n/a
RSI	55.49
Earnings Date	Feb 2, 2026

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabet...

• Industry: Pharmaceutical Preparations
• Founded: 1717
• Employees: 4,287
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ON4

Financial Performance

In fiscal year 2025, Ono Pharmaceutical's revenue was 486.87 billion, a decrease of -3.14% compared to the previous year's 502.67 billion. Earnings were 50.05 billion, a decrease of -60.89%.

Financial numbers in JPY